Aigen Investment Management LP, a well-known investment fund, announced on Tuesday that it has acquired a new position in Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), as disclosed by the Securities & Exchange Commission. The acquisition included 1,389 shares of the specialty pharmaceutical company’s stock, valued at approximately $221,000.
Jazz Pharmaceuticals is a biopharmaceutical company that specializes in developing and commercializing innovative pharmaceutical products in various therapeutic areas such as narcolepsy, oncology, pain management, and psychiatry. Its impressive product portfolio includes Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos and Defitelio.
Jazz Pharmaceuticals Plc stock opened at $127.55 on Friday with a market capitalization of $8.16 billion. The company has reported negative earnings per share (EPS) over the last twelve months with a price-to-earnings ratio of -50.22. Despite this seemingly discouraging statistic, the company’s price-to-earnings growth (PEG) ratio is promisingly low at 0.73 which may suggest now may be an excellent time for investors to consider investing.
The firm also has impressive financials; according to its latest SEC filing findings; its current ratio sits at 3.06 with significant liquidity for any eventualities while also maintaining emergency funds with a quick ratio of 2.32 in place should the need arise.
Despite having experienced slight turbulence resulting from minor downturns since hitting an all-time high of $163.31 some months back,Jazz Pharmaceuticals presents itself as an invaluable investment hub worth considering given its vast experience and expertise in identifying cutting-edge pharmaceutical products in different sectors while providing investors with tidy returns within an attractive PEG ratio environment.
In conclusion,it’s safe to say Jazz pharmaceuticals through solid fundamentals coupled together with a list of impressive products set it apart from the competition in an ever-changing pharmaceutical industry. Jazz Pharmaceuticals’ stock, $JAZZ may be an excellent investment opportunity for investors seeking to build quality portfolios with significant returns and low risks.
Jazz Pharmaceuticals Rises Higher with Institutional Investors and Positive Analyst Ratings
Jazz Pharmaceuticals: A Biopharmaceutical Company on the Rise
Jazz Pharmaceuticals Plc is a biopharmaceutical company that specializes in identifying, developing, and commercializing pharmaceutical products in various areas such as narcolepsy, oncology, pain, and psychiatry. Headquartered in Dublin, Ireland and with operations across the globe, Jazz has been experiencing significant growth over recent months. Not only have several institutional investors increased their shareholdings, but several analysts have also rated the stock positively.
Institutional Investors Boost Stakes
UMB Bank n.a. raised its stake in shares of Jazz Pharmaceuticals by 2,171.4% in Q4 2020 while Quadrant Capital Group LLC boosted its position by 90.3% during Q3 2020. Huntington National Bank acquired a new stake during Q3 2020 worth $31k and U.S. Capital Wealth Advisors LLC bought shares worth about $53k in Q4 2020. Furthermore, IFP Advisors Inc lifted its stake by 26.5% during the same quarter.
Analysts’ Viewpoint
StockNews.com assigned a “strong-buy” rating for the company on May 18th while HC Wainwright reissued a “buy” rating with a price target of $204 on March 6th. Royal Bank of Canada lowered their price objective from $207 to $202 on May 11th while The Goldman Sachs Group assigned it a “buy” rating with a target price raised from $190 to $212 on March 3rd. Finally, Needham & Company LLC upped its target price from $205 to $212 on May 11th.
Upward Trend Continues
With analysts’ positive ratings and increased investments from institutional shareholders, Jazz Pharmaceuticals seems poised for continued success moving forward. The company reported negative net margins of around -4%, but many analysts remain bullish on its prospects. The company’s product portfolio, which includes Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio has been performing well and Jazz Pharmaceuticals expects to post 14.75 earnings per share by the end of the year.
In conclusion, Jazz Pharmaceuticals’ focus on bleeding-edge products in growing sectors such as pain and oncology could present significant growth opportunities for the company in the near future. As a result, investors should keep an eye on their now rising stock prices.
Discussion about this post